We evaluated the impact of genetic changes within p6Gag gene on the virological response (VR, mean decrease in plasma viral load at week 12) to unboosted amprenavir (APV). Gag-protease fragments, including gag p2, p7, p1, p6 regions and whole protease (PR) were sequenced from baseline plasma specimens of 84 highly pre-treated but APV-naive patients included in the NARVAL (ANRS 088) trial. The correlation between baseline p6Gag polymorphism, PR mutations, baseline characteristics and VR to APV was analysed in univariate analysis. Insertions (P459Ins) within p6 protein, leading to partial or complete duplication of the PTAPP motif, were significantly associated with a decreased VR (P459Ins versus wild-type; –0.3 ±0.8 vs –1.1 ±1.2 log copies/ml, P=0.007) and were more frequent when the V82A/F/T/S PR mutation was present (P=0.020). In multivariate analysis, after adjustment on the predictive factors of the VR in the NARVAL trial and on the PR mutations linked with response, there was a strong trend to an association (P=0.058) between the presence of P459Ins and an altered VR. In conclusion, these results suggest that insertions in the p6 region of HIV-1 gag gene may affect the VR, in highly pre-treated patients receiving an unboosted APV-containing regimen.
References
1.
PalellaF.J.Jr., DelaneyK.M., MoormanA.C., LovelessM.O., FuhrerJ., SattenG.A., AschmanD.J., & HolmbergS.D.Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.New England Journal of Medicine1998; 338: 853–860.
2.
DoyonL., CroteauG., ThibeaultD., PoulinF., PiloteL., & LamarreD.Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors.Journal of Virology1996; 70: 3763–3769.
3.
ZhangY.M., ImamichiH., ImamichiT., LaneH.C., FalloonJ., VasudevachariM.B., & SalzmanN. P.Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.Journal of Virology1997; 71: 6662–6670.
4.
MammanoF., PetitC., & ClavelF.Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients.Journal of Virology1998; 72: 7632–7637.
5.
BallyF., MartinezR., PetersS., SudreP., & TelentiA.Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.AIDS Research & Human Retroviruses2000; 16: 1209–1213.
6.
CoteH.C., BrummeZ.L., & HarriganP.R.Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.Journal of Virology2001; 75: 589–594.
7.
GallegoO., de MendozaC., CorralA., & SorianoV.Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug- naive and pretreated patients.Journal of Clinical Microbiology2003; 41: 1245–1247.
8.
KaufmannG.R., SuzukiK., CunninghamP., MukaideM., KondoM., ImaiM., ZaundersJ., & CooperD.A.Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.AIDS Research & Human Retroviruses2001; 17: 487–497.
9.
GatanagaH., SuzukiY., TsangH., YoshimuraK., KavlickM. F., NagashimaK., GorelickR.J., MardyS., TangC., SummersM., & MitsuyaH.Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors.Journal of Biological Chemistry2001; 10: 10.
10.
PetersS., MunozM., YerlyS., Sanchez-MerinoV., Lopez-GalindezC., PerrinL., LarderB., CmarkoD., FakanS., MeylanP., & TelentiA.Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein.Journal of Virology2001; 75: 9644–9653.
11.
MeynardJ.L., VrayM., Morand-JoubertL., RaceE., DescampsD., PeytavinG., MatheronS., LamotteC., GuiramandS., CostagliolaD., Brun-VezinetF., ClavelF., & GirardP.M.Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial.AIDS2002; 16: 727–736.
12.
RaceE., DamE., ObryV., PaulousS., & ClavelF.Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies.AIDS1999; 13: 2061–2068.
13.
ThompsonJ.D., HigginsD.G., & GibsonT.J.CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.Nucleic Acids Research1994; 22: 4673–4680.
14.
PasquierC., MillotN., NjouomR., SandresK., CazabatM., PuelJ., & IzopetJ.HIV-1 subtyping using phylogenetic analysis of pol gene sequences.Journal of Virological Methods2001; 94: 45–54.
15.
VrayM., MeynardJ., DalbanC., Morand-JoubertL., ClavelF., Brun-VezinetF., PeytavinG., CostagliolaD., & GirardP-M. for the Narval Trial Group Predictors of the virological response to a change in the antiretroviral treatment regimen in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).Antiviral Therapy2003; 8: 427–434.
16.
MaguireM. F., GuineaR., GriffinP., MacmanusS., ElstonR.C., WolframJ., RichardsN., HanlonM.H., PorterD.J.T., WrinT., ParkinN., TisdaleM., FurfineE., PetropoulosC., SnowdenB.W., & KleimJ.P.Changes in human immunodeficiency virus Type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.Journal of Virology2002; 76: 7398–7406.
17.
MaguireM., MacManusS., GriffinP., GuineaC., HarrisW., RichardsN., WolframJ., TisdaleM., SnowdenW., & KleimJ. P.Interaction of HIV-1 protease and gag gene mutations in response to amprenavir-selective pressure exerted in amprenavir-treated subjects-contribution of Gag p6 changes L449F and P453L.Antiviral Therapy2001; 6(Suppl. 1): 48.
18.
MaguireM., ShortinoD., KleinA., HarrisW., ManohitharajahV., TisdaleM., ElstonR., YeoJ., RandallS., XuF., ParkerH., MayJ., & SnowdenW.Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors.Antimicrobial Agents & Chemotherapy2002; 46: 731–738.
19.
SchmidtB., KornK., MoschikB., PaatzC., UberlaK., & WalterH.Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors.Antimicrobial Agents & Chemotherapy2000; 44: 3213–3216.
20.
DescampsD., MasquelierB., MametJ., CalvezV., RuffaultA., TellesF., GoetschelA., GirardP.M., Brun-VezinetF., & CostagliolaD.A genotypic sensitivity score for amprenavir based on genotype at baseline and virological response.5th International Workshop on HIV Drug Resistance & Treatment Strategies. Scottsdale, Ariz., USA, 4–8 June 2001.
21.
MarcelinA.G., LamotteC., DelaugerreC., KtorzaN., Ait MohandH., CacaceR., BonmarchandM., WirdenM., SimonA., BossiP., BricaireF., CostagliolaD., KatlamaC., PeytavinG., & CalvezV.Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.Antimicrobial Agents & Chemotherapy2003; 47: 594–600.
22.
KochN., YahiN., FantiniJ., & TamaletC.Mutations in HIV-1 gag cleavage sites and their association with protease mutations.AIDS2001; 15: 526–528.
23.
IbeS., ShibataN., UtsumiM., & KanedaT.Selection of human immunodeficiency virus type 1 variants with an insertion mutation in the p6(gag) and p6(pol) genes under highly active antiretroviral therapy.Microbiology & Immunology2003; 47: 71–79.
24.
KondoE., & GottlingerH.G.A conserved LXXLF sequence is the major determinant in p6gag required for the incorporation of human immunodeficiency virus type 1 Vpr.Journal of Virology1996; 70: 159–164.
25.
GottlingerH.G., DorfmanT., SodroskiJ.G., & HaseltineW.A.Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release.Proceedings of the National Academy of Sciences, USA1991; 88: 3195–3199.
26.
YuX.F., DawsonL., TianC.J., FlexnerC., & DettenhoferM.Mutations of the human immunodeficiency virus type 1 p6Gag domain result in reduced retention of Pol proteins during virus assembly.Journal of Virology1998; 72: 3412–3417.
27.
DemirovD.G., OrensteinJ.M., & FreedE.O.The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner.Journal of Virology2002; 76: 105–117.
28.
BatesM., ChappeyC., BatesS., LimoliK., WrinT., & ParkinN.Modulation of replication capacity in drug sensitive clade B HIV-1 by Protease and the C-terminal end of Gag.Antiviral Therapy2003; 8: S81.
29.
BrummeZ.L., ChanK.J., DongW.W.Y., WynhovenB., MoT., HoggR.S., MontanerJ.S.G., O'ShaughnessyM.V., & HarriganP.R.Prevalence and clinical implications of insertions in the p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy.Antiviral Therapy2003; 8: 91–96.
